CARDIOVASCULAR SYSTEMS INC 4
4 · CARDIOVASCULAR SYSTEMS INC · Filed Feb 25, 2009
Insider Transaction Report
Form 4
EASTON CAPITAL PARTNERS L P
10% Owner
Transactions
- Other
Warrant
2009-02-25+234,339→ 234,339 totalExercise: $5.71From: 2009-02-25Exp: 2014-02-24→ Common Stock (234,339 underlying) - Other
Warrant
2009-02-25+234,339→ 234,339 total(indirect: Held by Easton Hunt Capital Partners, L.P.)Exercise: $5.71From: 2009-02-25Exp: 2014-02-24→ Common Stock (234,339 underlying)
Holdings
- 87,499(indirect: Held by Easton Hunt Capital Partners, L.P.)
Warrant
Exercise: $5.71From: 2006-07-19Exp: 2011-07-19→ Series A Conv Preferred Stock (87,499 underlying) - 616,197
Series A Conv Preferred Stock
→ Common Stock (616,197 underlying) - 616,197(indirect: Held by Easton Hunt Capital Partners, L.P.)
Series A Conv Preferred Stock
→ Common Stock (616,197 underlying) - 166,667(indirect: Held by Easton Hunt Capital Partners, L.P.)
Warrant
Exercise: $6.00From: 2008-09-12Exp: 2013-09-12→ Common Stock (166,667 underlying) - 87,499
Warrant
Exercise: $5.71From: 2006-07-19Exp: 2011-07-19→ Series A Conv Preferred Stock (87,499 underlying)
Footnotes (2)
- [F1]Each share of Series A convertible preferred stock is convertible at any time, at the holder's election, into 1.01 shares of common stock and has no expiration date.
- [F2]Holders of approximately 68% of the outstanding preferred stock entered into an agreement with the Company whereby effective immediately prior to the effective time of the merger of the Company with Replidyne, Inc., all preferred stock will convert into shares of common stock. The warrants were issued pro rata to each preferred shareholder, based on the percentage of preferred stock held, in consideration for entering into such conversion agreement.